Against the growing epidemic of Alzheimer's disease
(development for a novel small peptide)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
Tasly Pharmaceutical Co., Ltd. and ProteoTech, Inc. today announced an agreement to co-develop ProteoTech's novel small molecule therapeutic, Exebryl-1®, for the treatment of mild-to-moderate Alzheimer's disease. Exebryl-1® has been shown to inhibit beta-amyloid protein aggregate formation in brain, as well as disaggregate amyloid plaques that are already present. The drug has also shown specificity against tau protein aggregates and may be the first therapeutic targeting beta-amyloid and tau protein associated with this disease. ProteoTech CEO, Steve Runnels said "The opportunity for this collaboration with a major international pharmaceutical company is very exciting for us. We are very fortunate to have Tasly as a partner and their experience in drug development, especially in China, provides an opportunity to accelerate Exebryl-1® through clinical development. We look forward to a successful Exebryl-1® collaboration with Tasly and the potential development of other promising technologies in our pipeline as well." Read more: pharmaceuticalonline.com
Milk containing proteins is brought about better fluid retention
Milk proteins could be more effective than carbohydrates at aiding fluid retention after exercise, according to new research. Read more: nutraingredients.com
No comments:
Post a Comment